Summary Eligibility Intervention Contact Us

Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Conditions

  • Duchenne Muscular Dystrophy

Recruitment Status

TERMINATED

Eligibility Criteria

Inclusion Criteria:

* Completed a clinical trial evaluating casimersen or golodirsen, per protocol.
* Is between 7 and 23 years of age, inclusive, at enrollment.

Other inclusion/exclusion criteria apply.

Phase

PHASE3

Gender

MALE

Min Age

7 Years

Max Age

23 Years

Download Date

2024-09-19

Principal Investigator

N/A

Intervention

Intervention Type

DRUG

DRUG

Intervention Name

Casimersen

Golodirsen

Contact

For more information and to contact the study team:

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy NCT03532542